ArticleJournal of translational medicine2025
TRIM32 promotes tumor immune evasion and impedes Anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Divergent functions of the RNA-binding protein, Mei-P26 in germline and somatic lineages ofFrontiers in cell and developmental biology · 2026Article
- TRIM family proteins: dual roles in tumor immunity.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe tumor microenvironment (TME) in gastric cancer (GC) exhibits immunosuppressive features that facilitate tumor advancement and obstruct the effectiveness of immunotherapy. The role of tripartite motif 32 (TRIM32) in the TME has not been extensively studied.
methodsGC mouse model was utilized along with flow cytometry analysis, transwell assays, and immunohistochemistry to investigate the impact of TRIM32 on tumor progression and macrophage. To uncover the mechanisms by which TRIM32 operates within the GC microenvironment, various molecular and biochemical methods were utilized, including RNA-sequencing, western blotting, quantitative reverse transcription-polymerase chain reaction, coimmunoprecipitation, and immunofluorescence.
resultsTRIM32 originating from tumors was found to be linked to poor prognosis and notably associated with tumor-associated macrophages (TAMs) in. In vitro experiments revealed that TRIM32 induced TAMs recruitment and M2-like polarization. Mechanismly, TRIM32 interacted with Phosphodiesterase 9 A (PDE9A) and activated the downstream phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) signaling pathway. Additionally, the reprogramming of TAMs by TRIM32 diminished the resistance to anti-PD-1 treatment in GC models.
conclusionTRIM32/PDE9A axis promotes immune evasion in tumors and hinders the effectiveness of anti-PD-1 treatment by inducing TAMs recruitment and M2-like polarization in GC. This research provides insight into the role of TRIM32 in modulating tumor immunity and suggests that TRIM32 could be a promising target to overcoming resistance to anti-PD-1 therapy in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.